SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


Schreiber, S, Khaliq-Kareemi, M., Lawrance, I.C., Thomsen, O.?. and Hanauer, S.B., McColm, J., Bloomfield, R., Sandborn, W.J., PRECISE 2 study investigators (2007) Maintenance therapy with certlizumab pegol for Crohn’s disease. New England Journal of Medicine, 357, 239-250.

has been cited by the following article:

  • TITLE: A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease

    AUTHORS: Shota Saito, Utako Shimizu, Zhang Nan, Junji Yokoyama, Mayumi Watanabe, Kenshi Terajima, Kohei Akazawa

    KEYWORDS: Cost-Effectiveness; Crohn’s Disease; Elemental Diet; Infliximab; Markov Model

    JOURNAL NAME: Health, Vol.6 No.1, January 26, 2014

    ABSTRACT: Although infliximab (IFX) is effective for inducing and maintaining remission in patients with Crohn’s disease (CD), it is much more expensive than other treatments. The aim of this study is to evaluate the cost-effectiveness of several therapies, including IFX, for moderately to severely active CD. A Markov cohort model was constructed to simulate treatment effectiveness and costs. Transition probabilities, utilities, direct medical costs, and productivity costs were estimated using the results of published research. The primary effectiveness measurement was quality-adjusted life years (QALYs), as estimated by the 15D instrument. Expected effectiveness and total costs were calculated for a 10-year period using a yearly discount rate of 3% for QALYs and costs. Multiple one-way sensitivity analyses were performed by varying parameters that were likely to change QALYs and costs. As compared with nonbiologic therapy, therapy with IFX alone resulted in more QALYs and lower costs for the 10-year period. Combination therapy with IFX and elemental diet yielded an additional 0.252 QALYs at an additional cost of $18,522 as compared with nonbiologic therapy over 10 years. The resulting incremental cost-effectiveness ratio (ICER) of combination therapy vs nonbiologic therapy was $73,500/QALY. Patient body weight was the most important factor for cost-effectiveness. In conclusion it was revealed that combination therapy with IFX plus elemental diet appears not to be a cost-effective treatment for moderately to severely active CD.